title: Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study.
abstract: Adjusted early estimates of the 2013/14 influenza vaccine effectiveness (VE) in Spain for all age groups was 35% (95% CI: -9 to 62), 33% (95% CI: -33 to 67) and 28% (95% CI: -33 to 61) against any influenza virus type, A(H1N1)pdm09 and A(H3N2) viruses, respectively. For the population targeted for vaccination, the adjusted VE was 44% (95% CI: -11 to 72), 36% (95% CI: -64 to 75) and 42% (95% CI: -29 to 74), respectively. These preliminary results in Spain suggest a suboptimal protective effect of the vaccine against circulating influenza viruses.
authors.affiliation: National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Jimenez-Jorge
authors.forename: F
authors.initials: F
authors.lastname: Pozo
authors.forename: S
authors.initials: S
authors.lastname: de Mateo
authors.forename: C
authors.initials: C
authors.lastname: Delgado-Sanz
authors.forename: I
authors.initials: I
authors.lastname: Casas
authors.forename: M
authors.initials: M
authors.lastname: Garcia-Cenoz
authors.forename: J
authors.initials: J
authors.lastname: Castilla
authors.forename: R
authors.initials: R
authors.lastname: Sancho
authors.forename: L
authors.initials: L
authors.lastname: Etxebarriarteun-Aranzabal
authors.forename: C
authors.initials: C
authors.lastname: Quinones
authors.forename: E
authors.initials: E
authors.lastname: Martinez
authors.forename: T
authors.initials: T
authors.lastname: Vega
authors.forename: A
authors.initials: A
authors.lastname: Garcia
authors.forename: J
authors.initials: J
authors.lastname: Gimenez
authors.forename: J M
authors.initials: JM
authors.lastname: Vanrell
authors.forename: D
authors.initials: D
authors.lastname: Castrillejo
authors.forename: A
authors.initials: A
authors.lastname: Larrauri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011159:Population Surveillance; D013030:Spain / Q000453:epidemiology; D014611:Vaccination; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines